Encompass Health Corporation (EHC) saw its stock price soar 5.22% on Friday in the pre-market trading session, outperforming the broader market. This surge can be attributed to positive analyst commentary following the company's recent quarterly earnings report.
Barclays raised its price target on EHC to $118 from $116 while maintaining an Overweight rating on the shares. The analysts cited the company's strong Q4 performance as the driving factor behind their increased price target.
Additionally, Truist Financial's David S. Macdonald reiterated a Buy rating on Encompass Health, expressing confidence in the company's growth prospects. Macdonald's report highlighted the company's solid financials and positive outlook.